Find a Clinical Trial
The American Lung Association recommends considering clinical trials as soon as you are diagnosed, and every time you must make a treatment decision. Clinical trials are carefully monitored scientific research studies that test how well new medical approaches work in people. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease.A Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
To evaluate the safety and tolerability of ADXS-503, administered as monotherapy in Part A and in combination with pembrolizumab in Part B, and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD). As well, to characterize the preliminary anti-tumor activity of ADXS-503, administered in combination with pembrolizumab in Part C, per RECIST v1.1.
View Details
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo
The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.
View Details
A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced NON-SMALL CELL LUNG CANCER (LA NSCLC)
View Details
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of the study is to compare ociperlimab in combination with tislelizumab and pembrolizumab in patients with untreated advanced or metastatic non-small cell lung cancer and a specific tumor biomarker.
View Details
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent NSCLC
The purpose of this study is to assess the safety profile of nivolumab plus relatlimab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves progression free survival (PFS) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell LUNG CANCER (NSCLC).
View Details
ARISE and ENCORE Studies for Patients with MAC Lung Disease
To evaluate a potential treatment for MAC lung infection and its impact on symptoms including
respiratory discomfort and fatigue.
View Details
CASCADE-LUNG
Purpose or description of this study: We are recruiting approximately 15,000 individuals for a large-scale study to help determine the ability of our simple, blood-based screening technology to detect lung cancer accurately and reliably.
View Details
Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis (RheSolve)
This is a prospective, randomized, parallel group, double-blind, sham-controlled, multicenter clinical trial following patients to 2 years. The objective is to assess the safety and effectiveness of Bronchial Rheoplasty for the treatment of the symptoms of chronic bronchitis in adult COPD patients with moderate to severe chronic bronchitis. A total of 270 patients will be randomized at up to 40 study centers in the United States, Canada, and Europe.
View Details
Exablate
The primary objective is to evaluate the safety and efficacy of blood brain barrier disruption using the Exablate Type 2 system in adult subjects with brain metastases of NSCLC origin that are either undergoing or have planned standard of care pembrolizumab monotherapy as compared to subjects that are undergoing standard of care pembrolizumab without Exablate blood brain barrier disruption.
View Details
Gates MRI- COD-01-T01-01 Amendment 1
A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.
View Details
